Drugs and patents in ATC class H02C - ANTIADRENAL PREPARATIONS

Last updated: July 7, 2026

ATC class H02C (antiadrenal preparations) covers drugs that suppress adrenal steroid production or block adrenal steroid activity, most notably metyrapone (CYP11B1/2 inhibitor) and osilodrostat (steroidogenesis inhibitor). Patent estates in this class are fragmented by active ingredient, oral solid-state formulations, and use patents (often for congenital adrenal hyperplasia, Cushing syndrome, and related endocrine indications). Exclusivity timelines are driven by the last composition-of-matter and by FDA exclusivities linked to NDA approvals (when applicable), with the biggest generic entry risk tied to Paragraph IV filings against active-ingredient patents once market exclusivity falls away.

Where to focus for market forecasting and IP risk

Metyrapone: older platform with multiple generic entrants; remaining value is indication-dependent and constrained by patent lifecycles that mostly predate current portfolios.
Osilodrostat: core modern growth driver for H02C; patent challenges are less about instant generic substitution and more about timing around process/composition claims and therapeutic use coverage.
Depot or specialized delivery formulations (where they exist): narrower claim scope, but could delay generic equivalence if protected by formulation and manufacturing method patents.

Which drugs are in ATC Class H02C (antiadrenal preparations) and how do they segment the market?

ATC H02C is defined by antiadrenal pharmacology. In practice, the market segments by mechanism, indication, and regulatory footprint.

What are the key active ingredients in H02C?

Metyrapone
Osilodrostat
Other antiadrenal steroidogenesis modulators can appear in national formularies, but the commercial and patent visibility in this class concentrates on metyrapone and osilodrostat.

How is demand split across endocrine indications?

Antiadrenal drugs typically target:

Cushing syndrome (including endogenous hypercortisolism)
Congenital adrenal hyperplasia (CAH) (including 11β-hydroxylase deficiency and related steroidogenesis disorders)

Segmentation matters for patent value because use patents and label-anchored regulatory exclusivity are indication-specific. A patent covering Cushing syndrome use may not block generic entry for CAH if the label diverges and method-of-use claims are not infringed.

What patents protect osilodrostat (H02C) and how strong is the patent estate?

Core patent categories that typically protect osilodrostat

Osilodrostat market exclusivity has historically been supported by a layered estate:

Composition of matter (active ingredient and/or specific solid form)
Pharmaceutical composition (tablet/capsule formulation, excipient systems, dissolution profile)
Manufacturing processes (crystallization, milling, drying parameters)
Method-of-use (treatment of Cushing syndrome, CAH, cortisol-lowering dosing regimens)
Polymorph/solid-state (if separate claims exist by crystal form or hydrate/solvate status)

How to assess strength for generic entry risk

The strongest blocking patents are usually:

composition-of-matter claims with broad structural or crystalline coverage, and
solid-state form claims that prevent design-around.

The weaker blocking positions are often:

narrow formulation claim sets limited to a specific excipient matrix or particle-size range, and
dosing/regimen patents that can be avoided by labeling strategy or alternative clinical protocols, subject to infringement doctrine.

What is the Orange Book status of antiadrenal preparations, and where does listing concentrate?

In the US, generic challenge risk tracks Orange Book “listed drug” status:

If an active ingredient is an NDA and is listed with unexpired patents, then generics can file Paragraph IV certifications against those listed patents.
If the product is not Orange Book-listed (or only certain strengths are listed), challenge pathways change.

For H02C, the practical listing center is:

osilodrostat (if represented by an Orange Book-listed NDA with listed patents tied to Cushing/CAH labels), and
metyrapone, where older NDA/patent structures generally reduce live Orange Book leverage.

Market consequence: the highest expected Paragraph IV event risk in H02C concentrates where current listed patents map to osilodrostat’s core claims.

When does exclusivity end for H02C antiadrenal preparations, and what timelines govern generic entry?

Generic entry in H02C is governed by:

Patent expiration (composition-of-matter, method-of-use, solid-state)
Regulatory exclusivities (data exclusivity, pediatric exclusivity, if applicable)
Orphan exclusivity (when indications qualify, relevant if the drug has orphan-designated indications that affect exclusivity)
Label timing: even after exclusivity falls, generic entry depends on the ability to file with bioequivalence and on whether there are still unexpired patents tied to the brand’s listed drug.

Practical timeline logic used by generic filers

If a generic can certify “paragraph IV” against a patent that is later found invalid or not infringed, it can launch at risk.
If settlement is reached, launch is typically delayed until a defined date tied to patent expiration and/or dismissal of specific claims.

H02C implication: osilodrostat’s exclusivity and patent expiry dates create a concentrated window where multiple filers may submit Paragraph IV packages to be first-to-launch.

How many patents cover antiadrenal preparations (H02C) by claim type, and which are most likely to be attacked?

Typical attack pattern in steroidogenesis inhibitors

Generic filers target the broadest listed claims first, usually composition and method-of-use.
If composition claims remain enforceable, filers may attempt:
- carve-outs to non-infringing forms (for polymorph/solid-state),
- or “skinny label” strategies to avoid infringement of use claims mapped to protected indications.

Why claim-type concentration matters

Composition-of-matter patents tend to have the most “first-order” blocking effect.
Method-of-use patents create “label barrier” risk that can be managed if the generic can market only indications not covered by those claims.
Formulation/process patents can still delay approval if they lead to non-infringing design constraints, though they are often easier to design-around than core active-ingredient claims.

Which companies are challenging osilodrostat or antiadrenal patents via Paragraph IV, and how do settlement terms shape launch risk?

For this class-level briefing, the key business point is not just who files, but how often:

Paragraph IV filings are followed by early settlement that resolves multiple asserted patents, and
settlements include “pay-for-delay” economics or non-cash consideration tied to agreed launch dates.

Commercial takeaway: in H02C, a brand that settles early with at least one generic typically reduces uncertainty for the market by making launch dates predictable. The risk for investors and licensing counterparties is when filings cluster near the end of the patent term and settlements fail.

What patent litigation affects antiadrenal preparations, and which jurisdictions drive outcomes?

US as the main catalyst

The US framework is the dominant driver because:

Paragraph IV triggers litigation tied to approval timing.
Injunctions or delay settlements shape first generic entry and market share.

Other jurisdictions for parallel pressure

EP and national EU filings determine European commercial exposure.
UK and other EEA systems can influence settlement expectations by changing enforceability outcomes.

Market consequence: even when US patents dominate launch timing, European invalidation or narrowing can affect global licensing and re-pricing strategies.

How do generic entry risks differ between metyrapone and osilodrostat within H02C?

Metyrapone (older, more commoditized profile)

Patent estates are older and many composition protections have expired or expired by the time modern consolidation occurs.
Generic entry risk is mostly driven by regulatory and supply-chain execution, not by an active, tight patent wall.

Osilodrostat (modern, higher IP intensity)

Patent estates likely include multiple layers: composition, solid state, formulation, process, and method of use.
Generic entry risk is dominated by whether filers can:
- design around solid-state claims,
- avoid method-of-use infringement via label strategy, and
- survive validity and non-infringement challenges in court.

What formulations are protected for antiadrenal preparations, and do solid forms matter for generic design-around?

Formulation and solid-state focus

For steroidogenesis inhibitors, the most commercially consequential formulation patents usually cover:

tablet/capsule compositions with specific disintegration/dissolution targets,
solid form properties that affect stability and bioavailability,
manufacturing steps that control polymorph formation.

Why solid forms matter

If the brand’s “commercial product” corresponds to a specific polymorph or hydrate:

a generic may need to match that form to achieve bioequivalence,
which can become an infringement path if the form is claimed.

Which method-of-use patents cover CAH and Cushing syndrome treatments for H02C drugs?

Method-of-use patents are typically the second-largest hurdle after composition claims:

they can remain enforceable even after some composition claims are narrowed.
they also create “label-dependent” infringement analysis.

How “skinny label” changes infringement risk

If a generic enters with only non-protected indications, the brand’s ability to enforce method-of-use patents can weaken.
Enforcement strength depends on claim wording and whether the brand’s patent asserts align with the generic’s proposed label.

How does biosimilar risk apply to ATC H02C antiadrenal preparations?

Biosimilar risk is generally low for H02C because the class is dominated by small-molecule steroidogenesis inhibitors rather than biologics. As a result:

market exclusivity is driven by chemical patent estates and NDA exclusivities, not biosimilar pathways.

Commercial outlook: revenue exposure and market share pressure from upcoming patent cliffs in H02C

How to model revenue exposure

Revenue exposure is concentrated where:

there is a modern “brand franchise” (osilodrostat),
there are active unexpired patents with multiple listed claims, and
the brand has a large addressable population in the labeled indications.

The market stress test for investors and licensees is:

whether generic launch dates are “single date” events (clear patent cliff),
or “staggered” across multiple strengths/indications (method-of-use and formulation carve-outs).

Supply chain and payer dynamics amplify or mute IP risk

Even where IP ends, uptake depends on:

payer formulary decisions,
patient access programs for branded therapy,
and the speed of generic manufacturing qualification.

What generic launch scenarios exist for osilodrostat and other antiadrenal drugs in H02C?

Common US launch paths

Full label generic at Paragraph IV victory
- generic certification falls as valid/non-infringed
- launch date aligns with final nonappealable decisions or settlement
Skinny label entry
- generic avoids protected indications
- can occur even when method-of-use patents remain pending, depending on infringement landscape
Design-around solid form / formulation
- generic seeks bioequivalence with a non-infringing form or formulation
- success depends on solid-state claim scope and whether product performance matches

Key takeaways

ATC H02C antiadrenal preparations are IP-driven by layered protection around osilodrostat and less by remaining active patent leverage for metyrapone.
Generic entry risk concentrates where Orange Book-listed patents remain unexpired and where method-of-use claims can block full-label generics.
The most actionable diligence steps for licensing, investment, and litigation posture are:
- mapping listed patents by claim type (composition vs method-of-use vs formulation/process),
- tying each claim layer to label coverage and to practical skinny-label options,
- and monitoring Paragraph IV filing clusters and settlement patterns that set the real launch timetable.

FAQs

1) Which ATC H02C active ingredients have the highest patent intensity today?

Osilodrostat typically has the highest live patent intensity relative to metyrapone due to newer development and stronger composition/solid-state and method-of-use layering.

2) Do solid-state polymorph patents in H02C materially affect generic timing?

Yes. Where the marketed product corresponds to a claimed polymorph or solid state, generics face a design-around and bioequivalence risk that can extend litigation or settlement-driven launch delays.

3) How can a generic enter H02C without triggering method-of-use infringement?

By pursuing a skinny label that excludes indications covered by asserted method-of-use patents, or by proposing dosing and clinical positioning that avoids infringement of regimen claims, depending on claim language.

4) Are biosimilars a meaningful threat in antiadrenal (H02C) markets?

No. The class is predominantly small molecules, so biosimilar competition is not the main exclusivity and entry lever.

5) What drives payer and market uptake after patent expiration in H02C?

Beyond IP status, payer formulary access, patient assistance dynamics, and speed of generic manufacturing qualification determine how quickly volume shifts.

References (APA)

World Health Organization. (n.d.). ATC classification system: H02C antiadrenal preparations. WHO.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.

Subclasses in ATC: H02C - ANTIADRENAL PREPARATIONS